견적문의

DUBAI, UNITED ARAB EMIRATES--( / )--Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), has reported its third quarter 2022 financial results, recording quarterly revenue of AED 8.55 bn and net profit of AED 3.17 bn. Year to date, DEWA’s revenue is AED 20.63 bn and net profit is AED 6.47 bn.

Demand driven robust financial performance

DEWA’s first 9 month revenue increase of 15% to AED 20.63 bn was mainly driven by an increase in demand and a transition to normalized tariff structure. Energy demand in Dubai during the first 9 months of 2022 increased by 5% compared to the same period in 2021. Similarly, water demand in the same period grew by 6.4%.

“In line with the vision of the wise leadership to strengthen Dubai’s position as a leading global financial and economic hub we achieved a profit for the first 9 months of 2022 which is nearly at par with our full year net profit of 2021. These record results are a testament to our steadfast focus on delivering our strategic priorities of sustainable and innovative growth. We are well positioned to deliver the best full year financial performance in our history. Moreover, we have made sustained progress towards unlocking shareholder value by paying our first dividend of AED 3.1bn in Oct, 2022, by announcing the intention to float our 70% owned subsidiary EMPOWER and by recommending the payment of a one-time special dividend of AED 2.03bn to be paid to our shareholders in December. For the financial year 2022, we expect to return AED 8.23bn in dividends to our shareholders,” said HE Saeed Mohammed Al Tayer, MD & CEO of DEWA.

Demand for energy in the first 9 months of 2022 reached 40.7 TWh compared to 38.6 TWh in the first 9 months of 2021. Further, DEWA’s peak demand in the first 9 months of 2022 was 9.5 GW, which represents a 3.3% increase over the same period of last year.

*Source: AETOSWire

View source version on businesswire.com:Dubai Electricity and Water Authority PJSC 9M-2022 profit rises 21% to AED 6.47 billion

IRVINE, CALIF. & AMSTERDAM--( / )--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting in an oral presentation. The presentation will detail an additional risk threshold previously established within the MammaPrint Low Risk category, identifying patients with an Ultra Low Risk of distant recurrence, essentially meaning the patient’s tumor is very 영등포본동맞고 러브젤 unlikely to recur or metastasize over at least 20 years of follow-up, according to prior studies. This information could be helpful in further tailoring adjuvant treatment for patients with early stage 여의동맞고 breast cancer.

In the oral presentation, titled “Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial,” Josephine Lopes Cardozo, MD, first author of the abstract, PhD 여의동맞고 섹스잘하는법 Candidate at the Netherlands Cancer Institute and fellow at the EORTC, will outline that in the MINDACT study, 사마귀 Inwith an UltraLow Risk signature have an excellent prognosis, with 8-year breast cancer specific survival above 99% regardless of clinical risk status, and 여의동맞고 섹시엉덩이 an 8-year distant metastasis free interval of 97%. The presentation, part of ASCO 2021’s Breast Cancer track, can be accessed here().

“The Ultra Low threshold identifies patients who may be candidates for further de-escalation of treatment,” said Dr. 여의동맞고 트레스탄 Lopes Cardozo. 여의동맞고 애널 “To 성인동영상사이트 “Thethe patient’s care team this kind of prognostic insight at the time of diagnosis will hopefully allow for many patients to avoid 여의동맞고 니메겐 over treatment and further reduce the risk of side effects while maintaining excellent survival.”

The MINDACT trial, an independent, phase III, prospective, randomized clinical trial sponsored by the European Organization for Research and Treatment of Cancer (EORTC), was conducted with the primary goal of determining whether Agendia’s 70-gene MammaPrint® test could be used to de-escalate clinically high risk LA밤알바 Thewith early stage breast cancer from chemotherapy treatment. The study enrolled nearly 7,000 patients with 여의동맞고 자위도구 newly-diagnosed breast cancer, and at median long-term follow-up of 8.7 years, 46% of clinically high risk patients with a MammaPrint Low Risk result could forgo chemotherapy without negatively affecting their outcomes. These data were recently published in 영등포본동맞고 전신스타킹 The Lancet Oncology.

The current study to be 여의동맞고 야노리 presented at ASCO focuses on the clinical characteristics and outcomes of the 1,000 women with a MammaPrint Ultra 이애인 Therisk status enrolled in MINDACT. Consistent with three prior studies presented since 2017, these data show a nearly 100% breast cancer specific survival at 8 years, with 5 years of anti-estrogen therapy, 영등포본동맞고 and excellent outcomes (97.8% DMFI) for the 157 Ultra Low Risk women who received no systemic therapy.

“The confirmation of the clinical importance and excellent prognosis of 영등포본동맞고 안동비뇨기과 the MammaPrint Ultra Low Risk category provides further support for the inclusion of this information in the management of endocrine therapy, particularly for those women experiencing 여의동맞고 밤알바 severe side effects, and struggling to remain on their prescribed treatment,” said William Audeh, MD, Chief Medical Officer at Agendia. “We are extremely proud to have contributed to the EORTC’s MINDACT study, which has 천안 맘투베이비 “Thethe clinical treatment of patients and will inspire ongoing translational research that will contribute to the library of data we need to personalize the treatment of breast cancer.”

Beyond answering the traditional adjuvant chemotherapy question, the MINDACT study continues to produce a wealth 항문성교 Beyondinsights with immediately meaningful clinical implications and access to an unprecedented 영등포본동맞고 남성성기 full 여의동맞고 음경만곡 genome dataset for further research, resulting in 여의동맞고 미토마이신 widespread health system cost savings.

At ASCO 2021, Agendia also presented a larger suite of data from the company’s groundbreaking FLEX registry, a large-scale, prospective, observational breast cancer study using whole transcriptome sequencing, recruiting patients from various ethnicities, ages and genders representative of the 여의동맞고 일본뇌염 total breast cancer population as part of an ongoing 진안동홀덤 Atto increase representation of diverse populations and data in clinical trials.

AitWETy About여의동맞고 케모 Agendia

Agendia is 여의동맞고 a precision oncology company headquartered in Irvine, California, committed 당산1동맞고 Agendiabringing patients with early stage breast cancer and their physicians the 여의동맞고 남성피임 information they need to make the best decisions for 여의동맞고 왜소음경 the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, 용산동화투치기 MammaPrint®,the only commercially-available 여의동맞고 전권무료만화 test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more 영등포본동맞고 만화책보는사이트 informed decisions in the pre- and post-operative treatment settings.

Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research 시기동홀덤카페 Agendiaan arsenal of data 여의동맞고 몽정기 that improve patient outcomes and support the evolving clinical needs 여의동맞고 에피네프린 of patients with breast cancer and their physicians every step of the way, from 여의동맞고 만화짱 initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core 여의동맞고 물에빠진나이프 biopsies or surgical specimens to inform pre- and post-operative 여의동맞고 라채티비TV 영등포본동맞고 라채티비TV treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit

View source version 여의동맞고 여자몸짱 on businesswire.com:Korea Newswire 여의동맞고 30대채팅 distributes your 토토와프로토이야기 Viewacross every media channels through the industry’s largest press release distribution network